The final and largest stage of testing—hundreds to thousands of patients, designed to prove a drug works well enough for regulatory approval.Phase III trials are pivotal, large-scale (300–3,000+ patients), randomized controlled studies designed to confirm efficacy and monitor adverse reactions. Results form the primary basis for regulatory approval (NDA/BLA submission). Phase III trials require pre-specified primary endpoints, statistical powering, and often include active comparator arms. Approximately 50–60% of Phase III trials succeed. For the peptide compounds on Peptidings, Phase III completion distinguishes Tier 1 (Approved Drug) and advanced Tier 2 compounds from earlier-stage research.